Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mediwound ( (MDWD) ) just unveiled an update.
On February 19, 2026, MediWound Ltd. held an extraordinary general meeting in Israel at which shareholders representing about 30% of the company’s 12.8 million outstanding ordinary shares as of the January 16, 2026 record date were present, constituting a lawful quorum. The meeting focused on a single proposal to expand the company’s 2024 Share Incentive Plan, signaling continued use of equity-based compensation to retain and motivate key personnel.
Shareholders approved an increase of 300,000 ordinary shares reserved for issuance under the 2024 Share Incentive Plan, with 90.9% of votes cast in favor and 9.1% against, excluding abstentions, in accordance with Israeli Companies Law. The vote strengthens MediWound’s ability to grant future equity awards, potentially diluting existing holdings modestly while reinforcing long-term alignment between management, employees, and investors.
The most recent analyst rating on (MDWD) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.
Spark’s Take on MDWD Stock
According to Spark, TipRanks’ AI Analyst, MDWD is a Neutral.
Mediwound’s overall stock score is primarily impacted by its challenging financial performance, characterized by ongoing losses and negative cash flows. Technical analysis indicates a bearish trend, further weighing down the score. Valuation metrics are unfavorable due to negative earnings and the absence of dividends. While the earnings call provided some positive insights into future growth potential, these are overshadowed by current financial and operational challenges.
To see Spark’s full report on MDWD stock, click here.
More about Mediwound
MediWound Ltd. is an Israel-based biopharmaceutical company listed in the U.S. that develops and commercializes therapies, including products under a 2024 Share Incentive Plan that aligns employee and executive compensation with shareholder interests. The company operates under Israeli corporate law while accessing global capital markets through SEC-registered securities offerings.
Average Trading Volume: 104,058
Technical Sentiment Signal: Sell
Current Market Cap: $227.4M
See more data about MDWD stock on TipRanks’ Stock Analysis page.